Page 1056 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPter 75 Immunological Diseases of the Gastrointestinal Tract 1019

80. Wang J, Mayer L, Cunningham-Rundles C. Use of GM-CSF in the 87. Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM
treatment of colitis associated with chronic granulomatous disease. J syndrome: clinical and immunologic features of 79 patients. Medicine
Allergy Clin Immunol 2005;115:1092–4. (Baltimore) 2003;82:373–84.
81. Born M, Willinek WA, Hassan C. [Gastric outlet obstruction in chronic 88. Pachlopnik Schmid J, Canioni D, Moshous D, et al. Clinical similarities
granulomatous disease]. Z Gastroenterol 2002;40:511–16. and differences of patients with X-linked lymphoproliferative syndrome
82. Hahn KJ, Ho N, Yockey L, et al. Treatment with anakinra, a recombinant type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency).
IL-1 Receptor antagonist, unlikely to induce lasting remission in patients Blood 2011;117:1522–9.
with CGD colitis. Am J Gastroenterol 2015;110:938–9. 89. Patey-Mariaud de Serre N, Canioni D, Ganousse S, et al. Digestive
83. Lublin M, Bartlett DL, Danforth DN, et al. Hepatic abscess in patients histopathological presentation of IPEX syndrome. Mod Pathol
with chronic granulomatous disease. Ann Surg 2002;235:383–91. 2009;22:95–102.
84. Buckley RH. Primary cellular immunodeficiencies. J Allergy Clin 90. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the
Immunol 2002;109:747–57. Immune-related adverse effects of immune checkpoint inhibitors: a
85. Hsieh KH, Chang MH, Lee CY, et al. Wiskott-Aldrich syndrome and review. JAMA Oncol 2016;2:1346–53.
inflammatory bowel disease. Ann Allergy 1988;60:429–31.
86. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and
mutations affecting the interleukin-10 receptor. N Engl J Med
2009;361:2033–45.